ReproCELL Dirección

Dirección controles de criterios 2/4

El CEO de ReproCELL's es Shuji Yokoyama, nombrado en Nov 2005, tiene una permanencia de 18.42 años. posee directamente un 1.15% de las acciones de la empresa, con un valor de ¥141.36M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 6.8 años, respectivamente.

Información clave

Shuji Yokoyama

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	18.8yrs
Participación del CEO	1.1%
Permanencia media de la dirección	4.7yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Aug 05

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Jul 17

Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Feb 07

CEO

Shuji Yokoyama (56 yo)

18.8yrs

Permanencia

Dr. Shuji Yokoyama, Ph D serves as the Chief Executive Officer of ReproCELL Incorporated since 2020 and has been its President since November 2005. Dr. Yokoyama joined ReproCELL Inc. in 2004 as General Man...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Shuji Yokoyama	CEO, President & Representative Director	18.8yrs	sin datos	1.09% ¥ 129.1m
Daisuke Usui	COO & Director	no data	sin datos	0.20% ¥ 23.2m
Ramakrishna Modali	CEO of REPROCELL USA Ltd & CEO of Bioserve Biotechnologies India	4.7yrs	sin datos	sin datos
David Bunton	Chief Executive officer of REPROCELL Europe	4.7yrs	sin datos	sin datos

4.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 4978 se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shuji Yokoyama	CEO, President & Representative Director	18.8yrs	sin datos	1.09% ¥ 129.1m
Daisuke Usui	COO & Director	no data	sin datos	0.20% ¥ 23.2m
Yoshiyuki Yamakawa	Independent Outside Director	16.3yrs	sin datos	0.053% ¥ 6.3m
Nobuhisa Yamazaki	Outside Audit & Supervisory Board Member	2.3yrs	sin datos	sin datos
Takanori Kushida	Outside Audit & Supervisory Board Member	7.3yrs	sin datos	sin datos
Yoshiyuki Murai	Outside Audit & Supervisory Board Member	4.1yrs	sin datos	sin datos

7.3yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 4978 se considera experimentada (6.8 años de antigüedad promedio).

ReproCELL Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024

ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023

No independent directors

ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022

No independent directors

Recent updates

ReproCELL Incorporated to Report Q2, 2025 Results on Nov 13, 2024

First quarter 2025 earnings released: JP¥0.84 loss per share (vs JP¥0.85 profit in 1Q 2024)

ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

New minor risk - Share price stability

ReproCELL Incorporated to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024

New minor risk - Shareholder dilution

New minor risk - Profitability

ReproCELL Incorporated to Report Fiscal Year 2024 Results on May 13, 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

ReproCELL Incorporated to Report Q3, 2024 Results on Feb 09, 2024

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 20%

ReproCELL Incorporated to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ReproCELL Incorporated to Report Q1, 2024 Results on Aug 10, 2023

Forecast to breakeven in 2025

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023

Consensus estimates of losses per share improve by 56%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ReproCELL Incorporated to Report Q3, 2023 Results on Feb 10, 2023

Price target decreased to JP¥300

No independent directors

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 21%

ReproCELL Incorporated to Report Q1, 2023 Results on Aug 10, 2022

ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

No independent directors

ReproCELL Incorporated to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings released: JP¥1.08 loss per share (vs JP¥2.20 loss in 2Q 2021)

ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm

Consensus EPS estimates increase to -JP¥5.46

Forecast to breakeven in 2024

ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm

Full year 2021 earnings released: JP¥11.37 loss per share (vs JP¥14.26 loss in FY 2020)

ReproCELL Incorporated to Report Fiscal Year 2021 Results on May 14, 2021

New 90-day low: JP¥384

Third quarter 2021 earnings released: JP¥4.10 loss per share (vs JP¥3.18 loss in 3Q 2020)

Revenue and earnings beat expectations

Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

New 90-day high: JP¥449

ReproCELL Incorporated to Report Q3, 2021 Results on Feb 12, 2021

Second quarter 2021 earnings released: JP¥2.20 loss per share

New 90-day low: JP¥373

ReproCELL Incorporated to Report Q2, 2021 Results on Nov 12, 2020

First quarter earnings released

Full year earnings released - JP¥14.26 loss per share

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad